组蛋白去乙酰化酶抑制剂在 HR 阳性 HER-2 阴性晚期乳腺癌的研究进展

Histone deacetylases (HDACs) are histone modifying enzymes that can modulate epigenetic changes. HDACs are abnormally activated in some tumors, and their elevated expression correlates closely with tumor progression and drug resistance. HDAC inhibitors (HDACi) regulate epigenetic modifications in tumor cells controlling tumor cell proliferation, cell cycle, and DNA damage repair. HDACi can inhibit multiple oncogenic signaling pathways in breast cancer, which may reverse treatment resistance in hormone receptor (HR) positive human epidermal growth factor receptor-2 (HER-2) negative breast cancer. This review summarizes research progress regarding using HDACi to treat HR positive HER-2 negative advanced breast cancer and discusses the prospects of its application in breast cancer treatment.